TickericonsBuy · $49

Company

Vertex Pharmaceuticals logo

VRTXHealth CareAdded Sep 23, 2013

VRTX TrademarkTrademark
VRTX Full logoFull logo

About Vertex Pharmaceuticals

Vertex Pharmaceuticals is the global leader in cystic fibrosis treatment, with a CF franchise (Trikafta, Symdeko, Orkambi) that addresses roughly 90% of people with the underlying genetic mutation. Founded in 1989 and headquartered in Boston, the company has used CF profits to fund a pipeline that includes Casgevy — the first CRISPR gene-editing therapy approved in the U.S. and EU, co-developed with CRISPR Therapeutics for sickle cell and beta-thalassemia. Vertex is also developing pain therapies (Journavx, a non-opioid approved in 2025), kidney disease, type 1 diabetes (islet cell therapies), and Alpha-1 antitrypsin deficiency programs. The company is one of the most successful biotechs of the past two decades.

About the Vertex Pharmaceuticals logo

The Vertex Pharmaceuticals (VRTX) logo is part of the Tickericons pack — a hand-crafted set of logos for every company in the S&P 500. Each logo is manually redrawn to a consistent grid, weight, and corner radius so VRTX sits cleanly next to other tickers in cap tables, dashboards, equity research, and fintech UI.

You get two styles: the trademark (just the symbol, ideal for grids and tight UI) and the full logo (mark plus wordmark, ideal when there's room to breathe). Both ship as scalable SVG, high-resolution PNG, and reusable Figma components.

Vertex Pharmaceuticals was added to the S&P 500 on Sep 23, 2013 and is currently classified under the Health Care sector.

Index history

  • Sep 20, 2013 · Added to the S&P 500

    Market capitalization change.

Other Health Care companies

See all →

Get all S&P 500 logos

One-time payment. SVG, PNG, and a Figma library. Free updates as the index changes.